Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/EUCTR2008-001663-11-DE
EUCTR2008-001663-11-DEActive, not recruitingNot Applicable

Quantification of the DPP-4 inhibition-mediated enhancement of the activity of the entero-insular axis

Diabeteszentrum Bad Lauterberg0 sitesStarted: October 10, 2008Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions
Drugs

Trial Snapshot

Phase
Not Applicable
Status
Active, not recruiting
Sponsor
Study OverviewEligibility CriteriaInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional clinical trial of medicinal product

Eligibility Criteria

Sex
All

Inclusion Criteria

  • •Visit 1 (Screening):
  • •a. Patient has type 2 diabetes mellitus (T2DM) (according to ADA criteria). Note: an OGTT may be performed to confirm diagnosis of T2DM
  • •b. Patient is = 30 and = 75 years of age on the day of signing informed consent.
  • •c. Patient has a BMI that is = 25 and = 35 kg/m2.
  • •d. Patient is currently not on an OHA medication and has a Screening/Visit 1 HbA1c = 6.5% and = 9% or is on OHA monotherapy with metformin or a sulfonylurea and has a Screening/Visit 1 HbA1c = 6% and = 8.5%
  • •e. Patient is a male, or a female who is unlikely to conceive, as indicated by at least 1 yes” answer to the following questions:
  • •1) Patient is a male.
  • •2) Patient is a surgically sterilized female.
  • •3) Patient is a postmenopausal female = 45 years of age with > 2 years since last menses.
  • •4) Patient is a non-sterilized, premenopausal female and agrees to abstain from heterosexual activity or to use an adequate method of contraception to prevent pregnancy. Note: Acceptable methods of birth control are: hormonal contraceptive, intrauterine device (IUD), diaphragm with spermicide, contraceptive sponge, condom, or vasectomy.
  • •f. Patient understands the study procedures, alternative treatments available, and risks involved with the study, and voluntarily agrees to participate by giving written informed consent.
  • •g. Agreement to maintain prior diet and exercise habits during the full course of the study.
  • •h. Ability to comply with all study requirements.
  • •i. Patient has an FPG of = 110 mg/dL (6.1 mmol/L) and =220 mg/dL (12.2 mmol/L).
  • •Note: If the Visit 3 FPG does not meet this criterion AND is not consistent with the patient's recent fasting SBGM values, a single repeat measurement may be performed at the discretion of the investigator. If repeat value meets FPG inclusion criterion, patient may continue in the study.
  • •j. Patient is = 80% compliant with study medication during the single-blind placebo run-in (as determined by tablet count).
  • •Are the trial subjects under 18? no
  • •Number of subjects for this age range:
  • •F.1.2 Adults (18-64 years) yes
  • •F.1.2.1 Number of subjects for this age range
  • •F.1.3 Elderly (>=65 years) yes
  • •F.1.3.1 Number of subjects for this age range

Exclusion Criteria

  • •a. Patient has a history of type 1 diabetes mellitus or a history of ketoacidosis
  • •b. Patient is assessed by the investigator as possibly having type I diabetes confirmed with a C-peptide = 0.7 ng/mL (0.23 nmol/L). Note: Only patients assessed by the investigator as possibly having type I diabetes should have C-peptide measured at Visit 1.
  • •c. Patient has been taking oral anti-hyperglycemic agent (OHA) within the prior 12 weeks, except metformin or a sulfonylurea.
  • •d. Patient has required insulin therapy within the past 12 weeks. Note: patients who received a brief period of insulin treatment (e.g., several days during a hospitalization) and who are no longer requiring insulin treatment may participate.
  • •Patients Requiring Specific Treatments
  • •e. Patient is on a weight loss program and is not in the maintenance phase, or patient started weight loss medication (e.g., orlistat, sibutramine, or rimonabant) within the prior 8 weeks.
  • •f. Patient is on or likely to require treatment with = 2 consecutive days or repeated courses of pharmacologic doses of corticosteroids, or requires steroid replacement therapy (i.e., in patients with adrenal insufficiency)
  • •Exception: Topical or inhaled corticosteroids are permitted in the study.
  • •g. Patient is being treated with immunosuppressive or immunomodulating agents (e.g., cyclosporine, metotrexate).
  • •h. Patient is currently participating or has participated in a study with an investigational compound or device within 12 weeks or 5 half-lives of signing informed consent.
  • •i. Patient has undergone a surgical procedure within 4 weeks prior to signing informed consent. Exception: Patient with a history of minor surgery (i.e. using local anesthesia, like for removal of basal cell carcinoma, cataract, etc) within 4 weeks of signing informed consent and is fully recovered may participate.
  • •j. Patient has a history of intolerance or hypersensitivity to a DPP- 4- inhibitor or metformin or has any contraindication to DPP-4 inhibitors or metformin based upon label of the country of the investigational site.
  • •Concomitant Disease of Organs and Systems
  • •k. Patient has laboratory values as listed below:
  • •Parameter Values
  • •Creatinine Clearance < 70 mL/min
  • •ALT† > 2 times ULN
  • •AST† > 2 times ULN
  • •TSH Outside of normal range
  • •TG > 600 mg/dL (> 4.5 mmol/L)
  • •MDRD estimated creatinine clearance
  • •† Patients whose serum ALT or AST exceeds this limit may be retested one time if the investigator does not believe the value reflects the patient’s status.
  • •l. Patient has evidence of a significant cardiovascular disorder within 6 months of signing informed consent (e.g. acute coronary syndrome [e.g. MI or unstable angina], new or worsening angina; coronary artery intervention [e.g., CABG or PTCA]; stroke or transient ischemic neurological disorder).
  • •m. Patient has congestive heart failure that requires pharmacological treatment
  • •n. Patient has a systolic blood pressure of = 160 mmHg or diastolic blood pressure of = 95 mmHg. Note: Investigators are encouraged to maximize blood pressure control according to current guidelines. Patient may have blood pressure medication adjusted and be enrolled if repeat blood pressure measurement no longer meets exclusion criterion at Visit 3/Week -2.
  • •o. Patient has a history of malignancy. Exceptions: (1) Patients with adequately treated non-melanomatous skin carcinoma or carcin

Investigators

Sponsor
Diabeteszentrum Bad Lauterberg

Similar Trials

Recruiting
Not Applicable
Investigation of the impact of DPP-4 inhibition on serum brain natriuretic peptide level of diabetic patients with congestive heart failure.
JPRN-UMIN000015685Mitsui Memorial Hospital50
Not yet recruiting
Not Applicable
The inhibitory effects of the DPP-4 inhibitor for progression of diabetic nephropathy, in the patients with type 2 diabetes in Japan.The CKD patients with type 2 diabetes
JPRN-UMIN000011101Saitama Medical Center, Saitama Medical University50
Recruiting
Not Applicable
Examination about the influence that DPP-4 inhibitor gives for a left ventricle function in acute myocardial infarctioacute myocardial infarction, type2 diabetes mellitus
JPRN-UMIN000014539Center for Cardiovascular Interventions,Chiba University Hospital38
Completed
Not Applicable
Examination of the usefulness of DPP-4 inhibitor in the treatment of type 2 diabetesType 2 diabetes
JPRN-UMIN000011862aka Kinen Clinic10
Completed
Not Applicable
Investigation of pleiotropic effect of DPP-4 inhibitor, sitagliptin for type 2 diabetic patients with old myocardial infarctiotype 2 diabetic patients with old myocardial infarction
JPRN-UMIN000012562Department of Cardiology and Nephrology, Mie University Graduate School of Medicine, MUSIC FAIR Project Office30
Quantification of the DPP-4... | Clinical Trial